4-Amino-3-bromobenzonitrile | CAS:50397-74-5

We serve 4-Amino-3-bromobenzonitrile CAS:50397-74-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Amino-3-bromobenzonitrile

Chemical Name:4-Amino-3-bromobenzonitrile
CAS.NO:50397-74-5
Synonyms:4-Amino-3-bromobenzonitrile
2-Bromo-4-cyanoaniline
 
Physical and Chemical Properties:
Density 1.7±0.1 g/cm3
Boiling Point 300.3±27.0 °C at 760 mmHg
Melting Point 106-110 °C(lit.)
Molecular Formula C7H5BrN2
Molecular Weight 197.032
Flash Point 135.4±23.7 °C
Vapour Pressure 0.0±0.6 mmHg at 25°C
Index of Refraction 1.652
 
Specification:
Appearance:Light yellow to brown powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 4-Amino-3-bromobenzonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Bromo-4-cyanoaniline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Amino-3-bromobenzonitrile Use and application,4-Amino-3-bromobenzonitrile technical grade,usp/ep/jp grade.


Related News: Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.3-Chloro-2-iodopyridine manufacturer Commonly used generic drugs: the products whose patents have expired and the generic drugs of many companies have participated in the competition, and the market demand is large.N-FORMYL-L-LEUCINE supplier Commonly used generic drugs: the products whose patents have expired and the generic drugs of many companies have participated in the competition, and the market demand is large.Kojic Acid Dipalmitate vendor ICIG has agreed to offer employment to the unit’s approximately 120 employees upon closing, and plans to maintain operations at its primary location, a manufacturing facility in Liestal, Switzerland.Retrogenix holds two Queen’s Awards for Enterprise, the UK’s most prestigious acknowledgement of business performance. The company is headquartered near Manchester, UK, and has an office in Cambridge, MA.